Sciencast Management LP Purchases Shares of 4,263 IQVIA Holdings Inc. (NYSE:IQV)

Sciencast Management LP purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,263 shares of the medical research company’s stock, valued at approximately $838,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Private Trust Co. NA grew its stake in IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 47 shares in the last quarter. Pine Valley Investments Ltd Liability Co boosted its stake in shares of IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after acquiring an additional 50 shares during the period. Howard Capital Management Inc. boosted its stake in shares of IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after acquiring an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after acquiring an additional 56 shares during the period. Finally, Cypress Wealth Services LLC boosted its stake in shares of IQVIA by 4.8% during the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock worth $244,000 after acquiring an additional 57 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

IQVIA stock opened at $185.85 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52 week low of $179.28 and a 52 week high of $254.54. The stock has a market capitalization of $32.77 billion, a P/E ratio of 24.78, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The stock has a fifty day moving average of $194.94 and a 200-day moving average of $208.45.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Robert W. Baird reduced their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. UBS Group dropped their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. JPMorgan Chase & Co. dropped their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Finally, StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.